LNCB74

LNCB74 is an antibody-drug conjugate that binds specifically to B7-H4, a validated target on tumors.  B7-H4 protein is expressed on multiple tumor types, including many cancers specific to women (breast, ovarian and endometrial). LNCB74 has been specifically designed to reduce toxicity while improving tumor killing.  Our research showed LNCB74 has potent antitumor activity in in animal models, including models with low expression of B7-H4. LNCB74 is advancing towards an IND by end of 2024.

LNCB74 is advancing towards an IND by end of 2024 with on-going GMP manufacturing and initiation of GLP tox studies.

Expanded Access Policy

NextCure Expanded Access Policy can be viewed here.